Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

LncRNA PVT1 is increased in renal cell carcinoma and affects viability and migration in vitro

J. Bohosova, M. Kasik, A. Kubickova, K. Trachtova, M. Stanik, A. Poprach, O. Slaby

. 2022 ; 36 (6) : e24442. [pub] 20220420

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018195

Grantová podpora
NV18-03-00554 Ministerstvo Zdravotnictví Ceské Republiky
00209805, 65269705 Conceptual Development of Research Organizations
LM2018125 European Regional Development Fund-Project BBMRI-CZ
LM2018132 MEYS CR

BACKGROUND: Renal cell carcinoma is difficult to diagnose and unpredictable in disease course and severity. There are no specific biomarkers for diagnosis and prognosis estimation feasible in clinical practice. Long non-coding RNAs (lncRNAs) have emerged as potent regulators of gene expression in recent years. Aside from their cellular role, their expression patterns could be used as a biomarker of ongoing pathology. METHODS: In this work, we used next-generation sequencing for global lncRNA expression profiling in tumor and non-tumor tissue of RCC patients. The four candidate lncRNAs have been further validated on an independent cohort. PVT1, as the most promising lncRNA, has also been studied using functional in vitro tests. RESULTS: Next-generation sequencing showed significant dysregulation of 1163 lncRNAs; among them top 20 dysregulated lncRNAs were AC061975.7, AC124017.1, AP000696.1, AC148477.4, LINC02437, GATA3-AS, LINC01762, LINC01230, LINC01271, LINC01187, LINC00472, AC007849.1, LINC00982, LINC01543, AL031710.1, and AC019197.1 as down-regulated lncRNAs; and SLC16A1-AS1, PVT1, LINC0887, and LUCAT1 as up-regulated lncRNAs. We observed statistically significant dysregulation of PVT1, LUCAT1, and LINC00982. Moreover, we studied the effect of artificial PVT1 decrease in renal cell line 786-0 and observed an effect on cell viability and migration. CONCLUSION: Our results show not only the diagnostic but also the therapeutic potential of PVT1 in renal cell carcinoma.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018195
003      
CZ-PrNML
005      
20220804134619.0
007      
ta
008      
220720s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/jcla.24442 $2 doi
035    __
$a (PubMed)35441392
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bohosova, Julia $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
245    10
$a LncRNA PVT1 is increased in renal cell carcinoma and affects viability and migration in vitro / $c J. Bohosova, M. Kasik, A. Kubickova, K. Trachtova, M. Stanik, A. Poprach, O. Slaby
520    9_
$a BACKGROUND: Renal cell carcinoma is difficult to diagnose and unpredictable in disease course and severity. There are no specific biomarkers for diagnosis and prognosis estimation feasible in clinical practice. Long non-coding RNAs (lncRNAs) have emerged as potent regulators of gene expression in recent years. Aside from their cellular role, their expression patterns could be used as a biomarker of ongoing pathology. METHODS: In this work, we used next-generation sequencing for global lncRNA expression profiling in tumor and non-tumor tissue of RCC patients. The four candidate lncRNAs have been further validated on an independent cohort. PVT1, as the most promising lncRNA, has also been studied using functional in vitro tests. RESULTS: Next-generation sequencing showed significant dysregulation of 1163 lncRNAs; among them top 20 dysregulated lncRNAs were AC061975.7, AC124017.1, AP000696.1, AC148477.4, LINC02437, GATA3-AS, LINC01762, LINC01230, LINC01271, LINC01187, LINC00472, AC007849.1, LINC00982, LINC01543, AL031710.1, and AC019197.1 as down-regulated lncRNAs; and SLC16A1-AS1, PVT1, LINC0887, and LUCAT1 as up-regulated lncRNAs. We observed statistically significant dysregulation of PVT1, LUCAT1, and LINC00982. Moreover, we studied the effect of artificial PVT1 decrease in renal cell line 786-0 and observed an effect on cell viability and migration. CONCLUSION: Our results show not only the diagnostic but also the therapeutic potential of PVT1 in renal cell carcinoma.
650    _2
$a nádorové biomarkery $x genetika $x fyziologie $7 D014408
650    12
$a karcinom z renálních buněk $x genetika $x patofyziologie $7 D002292
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a pohyb buněk $x genetika $7 D002465
650    _2
$a proliferace buněk $x genetika $7 D049109
650    _2
$a viabilita buněk $x genetika $7 D002470
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a lidé $7 D006801
650    12
$a nádory ledvin $x genetika $x patofyziologie $7 D007680
650    12
$a RNA dlouhá nekódující $x genetika $x metabolismus $x fyziologie $7 D062085
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kasik, Marek $u Department of Urology, The University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kubickova, Adela $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Trachtova, Karolina $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Stanik, Michal $u Department of Urologic Oncology, Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk Memorial Cancer Institute, Masaryk University, Brno, Czech Republic
700    1_
$a Poprach, Alexandr $u Department of Urologic Oncology, Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk Memorial Cancer Institute, Masaryk University, Brno, Czech Republic
700    1_
$a Slaby, Ondrej $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000284500584 $7 js20030220015
773    0_
$w MED00009990 $t Journal of clinical laboratory analysis $x 1098-2825 $g Roč. 36, č. 6 (2022), s. e24442
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35441392 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134613 $b ABA008
999    __
$a ok $b bmc $g 1821997 $s 1169438
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 36 $c 6 $d e24442 $e 20220420 $i 1098-2825 $m Journal of clinical laboratory analysis $n J Clin Lab Anal $x MED00009990
GRA    __
$a NV18-03-00554 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a 00209805, 65269705 $p Conceptual Development of Research Organizations
GRA    __
$a LM2018125 $p European Regional Development Fund-Project BBMRI-CZ
GRA    __
$a LM2018132 $p MEYS CR
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace